What is the main purpose of this 8-K filing?

The primary purpose of this 8-K filing is to announce a key leadership transition within Gilead Sciences, Inc. It details the appointment of John C. Martin as Executive Chairman and the promotion of John F. Milligan to Chief Executive Officer, along with his election to the Board of Directors. Additionally, it discloses executive compensation details, including 2015 bonuses, 2016 base salaries, and new equity awards.

When do the leadership changes take effect?

The leadership changes are effective March 10, 2016. This includes John C. Martin's transition to Executive Chairman and John F. Milligan's promotion to Chief Executive Officer and joining the Board of Directors.

How are the compensation structures changing for the key executives?

For John C. Martin, his 2016 target bonus opportunity as a percentage of base salary is decreasing from 155% to 100%, with his bonus solely based on company performance. For John F. Milligan, his 2016 target bonus opportunity is increasing from 100% to 150% of base salary, also tied solely to company performance. Both executives, along with other named officers, received significant equity awards for 2016.

What types of equity awards were granted, and what are their key features?

Executive officers received two types of equity awards: stock options and performance shares. The stock options have an exercise price equal to the closing price of common stock on February 1, 2016, and a maximum term of ten years. The performance shares are structured with a Total Shareholder Return (TSR) tranche (50% of value) and a revenue tranche (50% of value), divided into three annual subtranches, similar to the 2015 awards.

GILD 8-K: Leadership Changes

Summary

Gilead Sciences, Inc. (GILD) filed an 8-K on February 3, 2016, primarily announcing a significant leadership transition and associated compensation adjustments. Effective March 10, 2016, current CEO John C. Martin will transition to Executive Chairman, and President and COO John F. Milligan will be promoted to Chief Executive Officer. Dr. Milligan will also join the Board of Directors. This filing also details the 2015 bonus awards and 2016 base salaries for key executive officers, along with the 2016 equity awards. Notably, Dr. Martin's target bonus opportunity is reduced, while Dr. Milligan's is increased upon his promotion. Both executives, along with other named officers, received substantial equity awards comprising stock options and performance shares, indicating continued alignment of executive compensation with company performance and shareholder value.

Key Highlights

1Leadership Transition: John C. Martin to become Executive Chairman, John F. Milligan promoted to CEO and joins the Board of Directors, effective March 10, 2016.
2Executive Compensation Adjustments: 2015 bonuses and 2016 base salaries for named executive officers are detailed.
3Martin's Role Change: Dr. Martin's 2016 target bonus opportunity decreases from 155% to 100% of base salary, tied solely to company performance.
4Milligan's Promotion: Dr. Milligan's 2016 target bonus opportunity increases from 100% to 150% of base salary, tied solely to company performance.
5Significant Equity Awards: Executive officers received substantial equity awards (stock options and performance shares) with grant-date fair values ranging from $1.6 million to $11 million.
6Performance Share Structure: Equity awards include performance shares with both a Total Shareholder Return (TSR) tranche and a revenue tranche, divided into annual subtranches.

GILEAD SCIENCES, INC. 8-K Report, Executive Changes (Feb 3, 2016)

Summary

Key Highlights

Frequently Asked Questions